Event: Poster presentation: Safety and Efficacy 31 Week Data of ANAVEX 2-73 in a Phase 2a Study in Mild-Moderate Alzheimer’s Disease Patients Date/Time: Wednesday, July 27, 2016 1:00 p.m. to 2:00 p.m. EDT Location: Hall D/E, Metro Toronto Convention Centre, Toronto, ON
NEW YORK – June 23, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that preclinical data for ANAVEX 2-73,…
NEW YORK, NY – June 22, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug…
2016 Rett Syndrome Symposium, Itasca, IL N. Rebowe, J. Sprouse, D. Brunner, P. Kabitzke, L. Velisek, M. Benson, J. Veliskova, C. Missling View Presentation
Event: Presentation by Christopher U. Missling, PhD, President and Chief Executive Officer Date/Time: Thursday, June 23, 2016 at 3:50 p.m. Location: Red Oak Ballroom, Eaglewood Resort & Spa, Itasca, IL.
Gordon Research Conference for Fragile X and Autism-Related Disorders, Mount Snow, VT Patricia Cogram, Daniel Klamer, Nell Rebowe, Jeffrey Sprouse, Christopher U. Missling View Poster
14th International Symposium on Advances in Alzheimer Therapy, Athens, Greece Christopher U. Missling, PhD View Presentation
Shared clinical phenotypes and underlying pathophysiology of Autism-Related Disorders such as Fragile X and Rett syndrome, indicates that ANAVEX 2-73 could be of interest to investigate clinically in these disorders NEW YORK, NY – June 6, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics…
NEW YORK, NY – May 20, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug…
Detailed Data to be Presented at Upcoming Scientific Meeting NEW YORK, NY – May, 18 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types…
